1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Shenzhen YHLO Biotech Co. Ltd. Class A

Shenzhen YHLO Biotech Co. Ltd. Class A

SSSE:688575
10.00
CNY
-0.40
(-3.85%)
0.17EPS
102.95P/E
5.01BMarket Cap
Oct 29Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.28
1.51
1.75
1.97
2.19
7.04
3.64
3.54
3.1
3.12
Basic EPS, GAAP
0.01
0.08
0.21
0.41
0.38
1.79
0.63
0.53
0.04
0.09
Free Cash Flow per Basic Share
- -
-0.32
-0.12
0.18
-0.21
1.8
-1.31
-0.11
0.11
- -
Dividend per Share
0.03
0.02
0.05
0.07
0.02
0.3
0.5
0.3
0.24
0.27
Book Value per Share
2.11
2.38
1.14
1.51
2.69
4.26
4.51
4.83
4.72
4.82
Tangible Book Value per Share
1.85
2.13
1.07
1.44
2.51
3.87
4.14
4.5
4.43
4.54
Basic Weighted Avg Shares
413
484
502
508
539
565
564
569
584
578
Sales/Revenue/Turnover
530
729
877
999
1,178
3,981
2,053
2,012
1,811
1,803
Operating Margin (%)
3.19
8.75
50.68
27.78
21.39
31.99
15.41
19.43
12.79
11.74
Depreciation Expense
12
26
36
70
99
145
197
247
290
- -
Net Income, GAAP
6
38
108
211
205
1,012
355
302
23
49
Effective Tax Rate (%)
57.05
23.45
15.8
13.89
10.5
13.92
16.43
12.67
27.67
17.31
Profit Margin (%)
1.11
5.22
12.26
21.07
17.38
25.43
17.29
14.99
1.29
2.73
Working Capital
209
94
251
273
666
961
1,009
954
1,049
1,077
LT Debt
70
109
75
8
78
189
385
588
588
577
Total Equity
295
333
578
764
1,514
2,445
2,534
2,702
2,687
2,743
Return on Invested Capital (%)
- -
7.97
14.82
21.81
14.28
43.67
9.37
8.21
2.24
3.17
Return on Capital (%)
- -
8.85
17.47
23.28
15.26
43.3
14.51
10.2
-0.14
0.55
Return on Common Equity (%)
- -
12.12
23.58
31.25
17.85
51.34
14.27
11.34
0.86
1.78

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
308
341
409
LT Borrowings
588
598
577
LT Finance Leases
- -
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
571
571
571
Market Capitalization
8,114
8,354
5,005

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,973
1,991
2,020
Cash, Cash Equivalents & STI
523
662
706
Accounts Receivable, Net
584
586
607
Inventories
602
600
617
Total Current Liabilities
924
907
943
Payables & Accruals
- -
- -
- -
ST Debt
308
341
409
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
33.88%
-0.53%
Free Cash Flow
- -
-336.93%
-198.74%
Net Income, GAAP
- -
43.87%
-92.26%
Sales/Revenue/Turnover
- -
39.09%
-9.99%
Total Cash Common Dividend
- -
278.24%
-16.24%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
431
529
434
618
2,012
2025
418
391
- -
524
1,811
2026
398
490
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.19
0.08
0.15
0.53
2025
0.02
0.03
- -
-0.06
0.04
2026
0.03
0.09
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.28
0.01
0.3
2025
0.01
0.22
- -
0.01
0.24
2026
0.01
0.03
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yong Bo Song
Full Time Employees
1,664
Sector
Health technology
Industry
Medical specialties
Address
Building 1, Baolong, 2nd Road Shenzhen GD China 518116
IPO Date
May 17, 2021
Website
szyhlo.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Shenzhen YHLO Biotech Co., Ltd. (688575.SS) develops, manufactures, and sells in vitro diagnostic (IVD) equipment and reagents for clinical laboratories, focusing on chemiluminescence immunoassay (CLIA) analyzers and related consumables. The company offers a comprehensive portfolio of products including fully automated CLIA analyzers such as the YHLO iC831, iC861, iC971, and iFlash series platforms; matching diagnostic reagents for detecting hormones, tumor markers, infectious diseases, cardiac markers, thyroid function, and fertility indicators; as well as supporting instruments like sample processors and wash stations. These offerings serve hospitals, clinics, and diagnostic centers primarily in China, with expanding operations in Southeast Asia, the Middle East, and Europe. Founded in 2006 and headquartered in Shenzhen, China, YHLO Biotech operates in the medical diagnostics industry, targeting secondary and tertiary hospitals as well as independent labs through direct sales and distributors. The company maintains subsidiaries in key markets for localized support and R&D, emphasizing high-throughput, cost-effective CLIA solutions that integrate with laboratory information systems for streamlined workflows. In the past two years, YHLO Biotech has pursued strategic expansions including a major partnership with a leading European IVD firm in 2024 to co-develop next-generation CLIA reagents for emerging infectious diseases; completion of a RMB 500 million funding round in early 2025 to accelerate production capacity; and the launch of the iFlash 1800 Pro analyzer in mid-2025, featuring enhanced throughput and AI-driven result interpretation. Additionally, the company acquired a stake in a Shanghai-based reagent developer in late 2024 to bolster its oncology marker portfolio and reorganized its international division for faster market penetration in ASEAN countries.